SequelSEC

LB PHARMACEUTICALS INC LBRX

Pharmaceutical Preparations · CIK 0001691082 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
Unavailable
Fiscal year ended 2026-06-30
Free cash flow
-$37.99M
Fiscal year ended 2026-06-30

LB PHARMACEUTICALS INC (LBRX) reported net income of -$51.60M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from LB PHARMACEUTICALS INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

LB PHARMACEUTICALS INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net income-$51.60MUnavailable-$11.47M-$3.56MUnavailableUnavailable-$5.07M-$14.18M-$27.63M-$16.22M
Research & development$44.15MUnavailable$8.48M$2.42MUnavailableUnavailable$376.00K$10.66MUnavailableUnavailable
Weighted-average diluted sharesshares 30.14MUnavailableUnavailableshares 5.81MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax income-$51.60MUnavailable-$11.47M-$3.56MUnavailableUnavailable-$5.07M-$14.18MUnavailableUnavailable
Income tax expense$0Unavailable$1.00K$0UnavailableUnavailable$1.00K$0UnavailableUnavailable
Diluted EPS$-1.71UnavailableUnavailable$-0.61UnavailableUnavailableUnavailable$-39.49UnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$9.77MUnavailable$5.39M$2.83MUnavailableUnavailable$5.16M$5.42MUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

LB PHARMACEUTICALS INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$283.11MUnavailable$250.17M$269.74MUnavailableUnavailable$22.98MUnavailableUnavailableUnavailable
Total assets$361.69MUnavailable$312.93M$320.75MUnavailableUnavailable$33.53MUnavailableUnavailableUnavailable
Current assets$355.30MUnavailable$308.43M$316.40MUnavailableUnavailable$28.88MUnavailableUnavailableUnavailable
Total liabilities$29.34MUnavailable$11.62M$10.52MUnavailableUnavailable$13.83MUnavailableUnavailableUnavailable
Current liabilities$23.56MUnavailable$7.44M$6.65MUnavailableUnavailable$8.11MUnavailableUnavailableUnavailable
Total equity incl. NCI$332.35MUnavailable$301.31M$310.22MUnavailableUnavailable-$94.55M-$91.45M-$77.44M-$50.45M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$114.26MUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$3.49MUnavailable$2.13M$2.59MUnavailableUnavailable$2.32MUnavailableUnavailableUnavailable

Cash flow

LB PHARMACEUTICALS INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$37.63MUnavailable-$18.10M-$3.37MUnavailableUnavailable-$5.66MUnavailableUnavailableUnavailable
Capital expenditures$363.00KUnavailable$40.00K$0UnavailableUnavailable$238.00KUnavailableUnavailableUnavailable
Investing cash flow$89.00KUnavailable-$40.00K-$44.84MUnavailableUnavailable$13.54MUnavailableUnavailableUnavailable
Financing cash flow-$19.00KUnavailable-$1.17M$303.73MUnavailableUnavailable$0UnavailableUnavailableUnavailable
Net change in cash-$37.56MUnavailable-$19.31M$255.52MUnavailableUnavailable$7.87MUnavailableUnavailableUnavailable
Stock-based compensation$4.90MUnavailable$2.34M$881.00KUnavailableUnavailable$2.28MUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

LB PHARMACEUTICALS INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow-$37.99MUnavailable-$18.14M-$3.37MUnavailableUnavailable-$5.90MUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio15.08xUnavailable41.44x47.60xUnavailableUnavailable3.56xUnavailableUnavailableUnavailable
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open LBRX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-26View SEC filing
10-Q · Filed 2025-11-06View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

6 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2026-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2026-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.